This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TRML Tourmaline Bio (TRML) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsHeadlinesInsider TradesOwnershipTrendsBuy This Stock About Tourmaline Bio Stock (NASDAQ:TRML) Get Tourmaline Bio alerts:Sign Up Key Stats Today's Range$47.98▼$47.9850-Day Range$47.74▼$48.1652-Week Range$13.27▼$48.27VolumeN/AAverage Volume592,710 shsMarket Capitalization$1.23 billionP/E RatioN/ADividend YieldN/APrice Target$47.94Consensus RatingHold Company Overview Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. Read More Tourmaline Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreTRML MarketRank™: Tourmaline Bio scored higher than 2% of companies evaluated by MarketBeat, and ranked 905th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingTourmaline Bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 9 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Tourmaline Bio is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageTourmaline Bio has received no research coverage in the past 90 days.Read more about Tourmaline Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tourmaline Bio are expected to decrease in the coming year, from ($3.02) to ($3.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tourmaline Bio is -13.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tourmaline Bio is -13.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTourmaline Bio has a P/B Ratio of 4.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for TRML. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTourmaline Bio does not currently pay a dividend.Dividend GrowthTourmaline Bio does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for TRML on MarketBeat in the last 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tourmaline Bio insiders have not sold or bought any company stock.Percentage Held by Insiders13.00% of the stock of Tourmaline Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.89% of the stock of Tourmaline Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tourmaline Bio's insider trading history. Receive TRML Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tourmaline Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRML Stock News HeadlinesTourmaline Bio acquisition completed by NovartisOctober 28, 2025 | msn.comNovartis announces expiration of Tourmaline Bio tender offerOctober 28, 2025 | msn.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.August 15 at 1:00 AM | Banyan Hill Publishing (Ad)Tourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRMLOctober 6, 2025 | businesswire.comTourmaline Bio (TRML) Price Target Decreased by 14.70% to 48.90September 30, 2025 | msn.comNovartis announces commencement of tender offer to acquire Tourmaline BioSeptember 29, 2025 | globenewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML)September 15, 2025 | prnewswire.comBMO Capital Downgrades Tourmaline Bio (TRML)September 15, 2025 | msn.comSee More Headlines TRML Stock Analysis - Frequently Asked Questions How were Tourmaline Bio's earnings last quarter? Tourmaline Bio, Inc. (NASDAQ:TRML) announced its earnings results on Wednesday, August, 13th. The company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.04. When did Tourmaline Bio IPO? Tourmaline Bio (TRML) raised $150 million in an IPO on Friday, May 7th 2021. The company issued 8,825,000 shares at a price of $16.00-$18.00 per share. What other stocks do shareholders of Tourmaline Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tourmaline Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST). Company Calendar Last Earnings8/13/2025Today8/15/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TRML Previous SymbolNASDAQ:TRML CIK1827506 Webtalaristx.com Phone502-398-9250FaxN/AEmployees44Year FoundedN/APrice Target and Rating Average Price Target for Tourmaline Bio$47.94 High Price Target$48.00 Low Price Target$47.50 Potential Upside/Downside-0.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($3.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$73.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-30.50% Return on Assets-29.63% Debt Debt-to-Equity RatioN/A Current Ratio24.68 Quick Ratio24.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.71 per share Price / Book4.10Miscellaneous Outstanding Shares25,692,000Free Float22,352,000Market Cap$1.23 billion OptionableOptionable Beta2.27 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:TRML) was last updated on 8/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
